Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Prothena Corporation plcNASDAQ: PRTA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns positive

Q1 FY2026 net income was $32.72M, compared with -$60.2M a year earlier. Trailing-twelve-month net income was -$151.18M. Over 3 fiscal years it compounded at +27.8% a year.

Context

  • Net income amounted to 2520.6% of revenue in FY2025, up 2430.1 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$1.13M (-99.5%) for the fiscal year ending Dec 2026, a slowdown from the +99.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$32.72M+251.6% QoQ
Last fiscal yearDec 2025
-$244.09M+99.6% YoY
LTMMar 2026
-$151.18M+37.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+154.4%-84.0%-238.4 pp
1 year+99.6%-99.5%-199.1 pp
3-year CAGR+27.8%-29.2%-57.0 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(244.09M) USD
Year-over-year change
-99.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +37.1% is the 3rd highest of 10, against a peer median of -2.6%.
  • Net income amounts to 260.9% of revenue for PRTA, versus a peer median of 1968.6%.
PRTA Competitors
Net Income for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PMNProMIS Neurosciences, Inc.LTM Jun 2026$39.72B USD+471244.2%+17.8%—
DNLIDenali Therapeutics Inc.LTM Jun 2026$511.45M USD+6.8%+16.3%14191.2%
BIIBBiogen Inc.LTM Jun 2026$417.6M USD-72.7%-24.1%4.2%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$222.39M USD-13.8%+21.9%—
ANNXAnnexon, Inc.LTM Mar 2026$196.48M USD+17.4%+13.3%—
PRTAProthena Corporation plcLTM Mar 2026$151.18M USD+37.1%+27.8%260.9%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$113.28M USD-2.6%+41.5%—
ACIUAC Immune S.A.LTM Dec 2025CHF 70.34M CHF+38.1%-1.7%1968.6%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$39.95M USD-14.1%-1.1%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$19.58M USD-41.2%+3.2%—
Peer median (excluding PRTA) —-2.6%+13.3%1968.6%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Depreciation & Amortization1.12M744K928K893K895K
Deferred Income Tax4.57M(11.13M)(15.69M)(9.35M)43.24M
Stock-Based Compensation24.66M31.32M40.91M45.96M37.64M
Change in Working Capital(10.4M)(18.8M)(20.53M)(67.94M)(4.17M)
Accounts Receivables15K0(5.16M)5.16M0
Inventory00(8.9M)00
Accounts Payables(492K)11.87M22.86M(18.3M)(15.78M)
Other Working Capital(9.93M)(30.67M)(29.33M)(54.8M)11.6M
Other Non-Cash Items5.69M6M7.5M2.69M2.91M
Operating Cash Flow92.61M(108.82M)(133.91M)(150.05M)(163.58M)
Capital Expenditures(575K)(464K)(2.81M)(298K)(138K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0037K00
Investing Cash Flow(575K)(464K)(2.77M)(298K)(138K)
Debt Repayment00000
Common Stock Issued174.79M223.62M23.58M0(139K)
Common Stock Repurchased000(353K)0
Dividends Paid00000
Other Financing Activities15.54M17.84M21.52M1.91M0
Financing Cash Flow190.33M241.46M45.1M1.55M(139K)
Effect of Forex Changes00000
Net Change in Cash282.36M132.17M(91.58M)(148.79M)(163.86M)
Free Cash Flow92.03M(109.29M)(136.72M)(150.35M)(163.72M)

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.